Structure via PubChem · Public domain (PubChem)
afatinib
Sign in to saveAlso known as BIBW2992, Gilotrif®, BIBW 2992, Afatinibum
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
Key facts
- Drug.licence_EU
- yes
- Drug.protein_bound
- 95%
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 645735594
- Drug.image
- Afatinib2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Afatinib 3D ball-and-stick 4G5P.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Gilotrif, Giotrif, Afanix
- Drug.MedlinePlus
- a613044
- Drug.DailyMedID
- Afatinib
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EB03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C24H25ClFN5O3
- Molecular weight
- 485.9 g/mol
- IUPAC name
- (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
- SMILES
- CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
- InChIKey
- ULXXDDBFHOBEHA-CWDCEQMOSA-N
- XLogP
- 3.6
- Polar surface area
- 88.6 Ų
- H-bond donors
- 2
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Research
2,631 papers- Afatinib.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2018
- Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
- Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.Current oncology (Toronto, Ont.) · 2023
- Afatinib-induced toxic epidermal necrolysis: A case report with a literature review.British journal of clinical pharmacology · 2024
- Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.Expert opinion on pharmacotherapy · 2018
via PubMed
Wikidata facts
- Mass
- 485.163
Show 5 more facts
- chemical formula
- C₂₄H₂₅ClFN₅O₃
- isomeric SMILES
- CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4
- canonical SMILES
- CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4
- World Health Organisation international non-proprietary name
- afatinib
- Commons category
- Afatinib
via Wikidata · CC0
~4 min read
Article
6 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- Clinical trials
- References
- External links
Afatinib, sold under the brand name Gilotrif among others, is a medication which is used to treat non-small cell lung carcinoma (NSCLC). It belongs to the tyrosine kinase inhibitor family of medications. It is taken by mouth.
It is mainly used to treating cases of NSCLC that harbour mutations in the epidermal growth factor receptor (EGFR) gene.